Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2011

01-10-2011 | Clinical Trial

Immunohistochemically defined subtypes and outcome in occult breast carcinoma with axillary presentation

Authors: Emilia Montagna, Vincenzo Bagnardi, Nicole Rotmensz, Giuseppe Viale, Giuseppe Cancello, Manuelita Mazza, Anna Cardillo, Raffaella Ghisini, Viviana Galimberti, Paolo Veronesi, Simonetta Monti, Alberto Luini, Paola Rafaniello Raviele, Mauro Giuseppe Mastropasqua, Aron Goldhirsch, Marco Colleoni

Published in: Breast Cancer Research and Treatment | Issue 3/2011

Login to get access

Abstract

The aim of this study is to evaluate the outcome of occult breast cancer (OBC) in patients with axillary presentation overall and according to the immunohistochemically defined tumour subtypes. We reviewed information on 15,490 consecutive primary breast cancer patients, who underwent surgery at the European institute of oncology between September 1997 and December 2008. Patients with OBC were compared with an equal number of patients with small invasive breast carcinomas (pT1) observed at the same institution during the same period, matched for year of surgery, age, nodal status and biological features. Eighty patients with OBC (study group) and 80 patients with early breast cancer (control group) were identified. There was no significant difference in the disease-free survival (5 years DFS 66 vs. 68% P = 0.91) and the overall survival (5 years OS 80 and 86% P = 0.99) between the OBC and control groups. A statistically significant worse outcome was observed within the group of OBC for patients with more than four involved lymph nodes and with triple negative tumours. The outcome of OBC patients is comparable with that of matched patients with small sized breast cancer. High risk of relapse and death was observed in OBC patients with triple negative tumours and extensive nodal involvement.
Literature
1.
Vilcoq JR, Calle R, Ferme F et al (1982) Conservative treatment of axillary adenopathy due to a probable subclinical breast cancer. Arch Surg 117:1136–1138PubMed
2.
Owen HW, Dockerty MB, Gray HK (1954) Occult carcinoma of the breast. Surg Gynecol Obstet 98:302–308PubMed
3.
Galimberti V, Bassani G, Monti S et al (2004) Clinical experience with axillary presentation breast cancer. Br Can Res and Treat 88:43–47CrossRef
4.
Newman LA, Singletary SE (2007) Overview of adjuvant systemic therapy in early stage breast cancer. Surg Clin North Am 87:499–509PubMedCrossRef
5.
Vezzoni P, Balestrazzi A, Bignami P et al (1979) Axillary lymph node metastases from occult carcinoma of the breast. Tumori 65:87–91PubMed
6.
Rosen PP, Kimmel M (1990) Occult breast carcinoma presenting with axillary lymph node metastases. A follow-up study of 48 patients. Hum Pathol 21:518–524PubMedCrossRef
7.
Merson M, Andreola S, Galimberi V et al (1992) Breast carcinoma presenting as axillary metastases without evidence of a primary tumour. Cancer 70:504–508PubMedCrossRef
8.
Kyokane T, Akashi-Tanaka S, Matsui T et al (1995) Clinicopathological characteristics of non-palpable breast cancer presenting as an axillary mass. Breast Cancer 2:105–112PubMedCrossRef
9.
Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752PubMedCrossRef
10.
de Ronde JJ, Hannemann J, Halfwerk H et al (2010) Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. Breast Cancer Res Treat 119(1):119–126PubMedCrossRef
11.
Cheang MC, Chia SK, Voduc D et al (2009) Ki67 Index, HER2 status, and prognosis of patients with Luminal B breast cancer. J Natl Cancer Inst 101(10):736–750PubMedCrossRef
12.
Hugh J, Hanson J, Cheang MC et al (2009) Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 27:1168–1176PubMedCrossRef
13.
Cancello G, Maisonneuve P, Rotmensz N et al (2010) Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer. Ann Oncol 21:1974–1981PubMedCrossRef
14.
Colleoni M, Cole BF, Viale G et al (2010) Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Clin Oncol 28(18):2966–2973PubMedCrossRef
15.
Colleoni M, Orvieto E, Nolè F et al (1999) Prediction of response to primary chemotherapy for operable breast cancer. Eur J Cancer 35:574–579PubMedCrossRef
16.
Kalbfleisch JD, Prentice RL (1980) The statistical analysis of failure time data. Wiley, San Francisco
17.
Gray RJ (1988) A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Statist 16:1141–1154CrossRef
18.
Svastics E, Ronay P, Bodo M (1993) Occult breast cancer presenting with axillary metastasis. Eur J Surg Oncol 19 (Suppl 1):575–580PubMed
19.
Jackson B, Scot-Conner C, Moulder J (1995) Axillary metastasis from occult breast carcinoma: diagnosis and management. Am Surg 61:431–434PubMed
20.
Pentheroudakis G, Lazaridis G, Pavlidis N (2010) Axillary nodal metastases from carcinoma of unknown primary (CUPAx): a systematic review of published evidence. Breast Cancer Res Treat 119:1–11PubMedCrossRef
21.
Panoff JE, Hurley J, Takita C et al (2011) Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiation. Breast Cancer Res Treat 899–906
22.
Dent R, Trudeau M, Pritchard KI et al (2007) Triple negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13(15 Pt 1):4429–4434PubMedCrossRef
23.
Bassarova AV, Nesland JM, Sedloev T et al (2005) Simultaneous bilateral breast carcinomas: a category with frequent coexpression of HER-2 and ER-alpha, high Ki-67 and bcl-2, and low p53. Int J Surg Pathol 13(3):239–240PubMedCrossRef
24.
Tanner M, Järvinen P, Isola J (2001) Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer. Cancer Res 15 61(14):5345–5348
25.
Iguchi C, Nio Y, Itakura M et al (2003) Heterogenic expression of oestrogen receptor between the primary tumour and the corresponding involved lymph nodes in patients with node-positive breast cancer and its implications in patient outcome. J Surg Oncol 83:85–93PubMedCrossRef
26.
Kamby C, Rasmussen BB, Kristensen B et al (1989) Oestrogen receptor status of primary breast carcinomas and their metastases. Relation to pattern of spread and survival after recurrence. Br J Cancer 60:252–257PubMedCrossRef
27.
Goldhirsch A, Glick JH, Gelber RD et al (1998) Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer Inst 90:1601–1608PubMedCrossRef
28.
Goldhirsch A, Ingle JN, Gleber RD et al (2009) Thresholds for therapies: highlights of the St Gallen International expert consensus on the primary therapy of early breast cancer. Ann Oncol 20(8):1319–1329PubMedCrossRef
Metadata
Title
Immunohistochemically defined subtypes and outcome in occult breast carcinoma with axillary presentation
Authors
Emilia Montagna
Vincenzo Bagnardi
Nicole Rotmensz
Giuseppe Viale
Giuseppe Cancello
Manuelita Mazza
Anna Cardillo
Raffaella Ghisini
Viviana Galimberti
Paolo Veronesi
Simonetta Monti
Alberto Luini
Paola Rafaniello Raviele
Mauro Giuseppe Mastropasqua
Aron Goldhirsch
Marco Colleoni
Publication date
01-10-2011
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2011
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-011-1697-6

Other articles of this Issue 3/2011

Breast Cancer Research and Treatment 3/2011 Go to the issue

Preclinical study

Acquisition of metastatic tissue from patients with bone metastases from breast cancer

Preclinical study

Multicentric breast cancer: clonality and prognostic studies

Clinical Trial

Drug switch because of treatment-related adverse side effects in endocrine adjuvant breast cancer therapy: how often and how often does it work?

Letter to the Editor

Associations between polymorphisms of tumor necrosis factor-α gene and breast cancer risk

Preclinical study

SOSTDC1 differentially modulates Smad and beta-catenin activation and is down-regulated in breast cancer

Review

Sentinel lymph node biopsy compared with axillary lymph node dissection in early breast cancer: a meta-analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits